Stocks · News reference

United Therapeutics Announces FDA Accepted NDA For Ralinepag In Pulmonary Arterial Hypertension, With PDUFA Target Action Date Of June 24, 2027

Aug 24, 2026, 11:07 AMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 17, 2026, 11:11 AMBenzinga Newsdesk
United Therapeutics Announces Full Enrollment Of TETON-PPF Study Evaluating Use Of Tyvaso Inhalation Solution For Treatment Of Progressive Pulmonary Fibrosis; Topline Data Expected In H2 Of 2027
Approximately 200,000 patients in the United States have PPF, with limited treatment optionsTopline data expected in the second half of 2027United Therapeutics Corporation (Nasdaq: UTHR) announced full enrollment of its
Read original at benzinga
UTHR
BenzingaAug 6, 2026, 5:57 PMBenzinga Newsdesk
RBC Capital Maintains Outperform on United Therapeutics, Lowers Price Target to $677
RBC Capital analyst Lisa Walter maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and lowers the price target from $704 to $677.
Read original at benzinga
UTHR
SEC EDGARAug 5, 2026, 10:33 AMSEC EDGAR
8-K filing — UNITED THERAPEUTICS Corp (UTHR)
Filed: 2026-08-05 AccNo: 0001082554-26-000028 Size: 432 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar
UTHR